UBS Group AG Sells 91,570 Shares of Emergent Biosolutions Inc. $EBS

UBS Group AG trimmed its position in Emergent Biosolutions Inc. (NYSE:EBS) by 20.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 347,805 shares of the biopharmaceutical company’s stock after selling 91,570 shares during the quarter. UBS Group AG’s holdings in Emergent Biosolutions were worth $4,299,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Legal & General Group Plc bought a new position in Emergent Biosolutions in the second quarter valued at approximately $31,000. Farther Finance Advisors LLC increased its stake in Emergent Biosolutions by 361.3% in the fourth quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 4,827 shares during the last quarter. Raymond James Financial Inc. bought a new position in Emergent Biosolutions in the second quarter valued at approximately $53,000. Baron Wealth Management LLC bought a new position in Emergent Biosolutions in the fourth quarter valued at approximately $133,000. Finally, BNP Paribas Financial Markets increased its stake in Emergent Biosolutions by 133.0% in the third quarter. BNP Paribas Financial Markets now owns 10,942 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 6,246 shares during the last quarter. 78.40% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. HC Wainwright cut their target price on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday, March 9th. Weiss Ratings lowered shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen lowered shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $12.00.

Emergent Biosolutions Stock Performance

Shares of Emergent Biosolutions stock opened at $8.49 on Friday. Emergent Biosolutions Inc. has a fifty-two week low of $5.61 and a fifty-two week high of $14.06. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.29 and a quick ratio of 2.08. The firm has a market capitalization of $438.17 million, a P/E ratio of -30.30 and a beta of 2.33. The company’s 50 day moving average price is $8.31 and its two-hundred day moving average price is $10.16.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.46. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%. The firm had revenue of $156.10 million for the quarter, compared to analyst estimates of $145.00 million.

Insider Buying and Selling at Emergent Biosolutions

In other news, Director Donald W. Degolyer sold 15,481 shares of Emergent Biosolutions stock in a transaction on Friday, May 1st. The shares were sold at an average price of $8.40, for a total transaction of $130,040.40. Following the transaction, the director owned 129,721 shares in the company, valued at approximately $1,089,656.40. The trade was a 10.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Katkin sold 15,481 shares of Emergent Biosolutions stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $8.28, for a total transaction of $128,182.68. Following the transaction, the director owned 96,294 shares in the company, valued at approximately $797,314.32. This trade represents a 13.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 61,925 shares of company stock worth $518,312 in the last three months. 6.00% of the stock is currently owned by company insiders.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.